{
    "organizations": [],
    "uuid": "a90e8b9e2b58b995e3995cf22da33f1ffe8c4e19",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-symbio-pharmaceuticals-says-termin/brief-symbio-pharmaceuticals-says-termination-of-development-of-patient-controlled-pain-management-drug-syb-p-1501-idUSL4N1PZ366",
    "ord_in_thread": 0,
    "title": "BRIEF-SymBio Pharmaceuticals says termination of development of patient-controlled pain management drug SyB P-1501",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 9 (Reuters) - SymBio Pharmaceuticals Ltd\n* Says it terminates the development of “IONSYS” or “SyB P-1501” in Japan, a drug for patient-controlled, short-term management of acute postoperative pain during hospitalization\nSource text in Japanese: goo.gl/ikDcFw\nFurther company coverage: (Beijing Headline News)\n ",
    "published": "2018-02-09T16:06:00.000+02:00",
    "crawled": "2018-02-10T14:03:42.003+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "symbio",
        "pharmaceutical",
        "ltd",
        "say",
        "terminates",
        "development",
        "ionsys",
        "syb",
        "japan",
        "drug",
        "management",
        "acute",
        "postoperative",
        "pain",
        "hospitalization",
        "source",
        "text",
        "japanese",
        "company",
        "coverage",
        "beijing",
        "headline",
        "news"
    ]
}